Publication: ALC4 and LY17

Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang T-C, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine 391: 320-333. 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2312948 

 

The addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-negative remission from BCP-ALL significantly improved overall survival.

 

 

Kuruvilla J, Rushton C, Villa D, Aslam M, Prica A, Abdel Samad N, Doucet S, Dudebout J, Fleury I, Fraser G, Larouche J-F, Shafey M, Skrabek P, Skamene T, Morin RD, Alcaide M, Ben-Neriah S, Lee D, Winch C, Shepherd LE, Scott DW, Crump M, Chen BE, Hay AE. A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma (ONLINE). British Journal of Haematology 2024. https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.19764

 

In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.